Washington D.C. – President Donald J. Trump signed an executive order on April 18, 2026, aimed at dramatically accelerating access to medical research and treatments based on psychedelic drugs for serious mental illnesses. The order, titled "Accelerating Medical Treatments for Serious Mental Illness," directs federal agencies to expedite the review, funding, and potential reclassification of compounds like ibogaine and psilocybin. The announcement drew a strong reaction from advocates, with W. Bryan Hubbard, CEO of Americans for Ibogaine, stating, > "FEDERAL PROHIBITION OF PSYCHEDELIC MEDICINE IN AMERICA IS OVER," as reported by The Big Weekend Show.
The executive order outlines several key directives to address the national mental health crisis, which affects over 14 million American adults. It mandates the Food and Drug Administration (FDA) to provide National Priority Vouchers to qualifying psychedelic drugs that have already received Breakthrough Therapy designations, potentially reducing approval timelines from years to weeks. This move is expected to streamline the process for bringing these experimental therapies to patients.
Furthermore, the order allocates at least $50 million through the Advanced Research Projects Agency for Health (ARPA-H) to support state-level psychedelic research programs. This funding aims to foster collaboration between federal and state governments, encouraging further studies into the therapeutic potential of psychedelics. The Department of Health and Human Services (HHS) and the FDA are also directed to work with the Department of Veterans Affairs (VA) and the private sector to increase clinical trial participation and data sharing, particularly for military veterans who often face higher rates of serious mental illness and suicide.
The strategic rationale behind the order emphasizes the urgent need for innovative treatments beyond existing prescription medications, especially for conditions resistant to standard therapies. It also directs the Attorney General to initiate reviews for rescheduling psychedelic substances upon successful completion of Phase 3 clinical trials and FDA approval, facilitating their medical use. The signing ceremony in the Oval Office included Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan, both vocal proponents of exploring psychedelics for mental health.
